Dowling & Yahnke LLC Biogen Inc. Transaction History

Dowling & Yahnke LLC

$215 Million
Q3 2022

A detailed history of Dowling & Yahnke LLC transactions in Biogen Inc. stock. As of the latest transaction made, Dowling & Yahnke LLC holds 3,717 shares of BIIB stock, worth $850,523. This represents 0.46% of its overall portfolio holdings.

Number of Shares

3,717

Previous 4,118 9.74%

Holding current value

$850,523

Previous $840,000 18.1%

% of portfolio

0.46%

Previous 0.04%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	SELL	$194.69 - $268.46 $78,070 - $107,652	-401 Reduced 9.74%	3,717 $992,000
Q2 2022 Aug 10, 2022	SELL	$187.54 - $223.02 $173,286 - $206,070	-924 Reduced 18.33%	4,118 $840,000
Q1 2022 May 04, 2022	SELL	$193.77 - $244.14 $186,600 - $235,106	-963 Reduced 16.04%	5,042 $1.06 Million
Q4 2021 Feb 10, 2022	SELL	$223.92 - $287.77 $125,171 - $160,863	-559 Reduced 8.52%	6,005 $1.44 Million
Q3 2021 Nov 12, 2021	SELL	$282.99 - $369.05 $82,067 - $107,024	-290 Reduced 4.23%	6,564 $1.86 Million

Q2 2021 Jul 21, 2021	SELL	$259.0 - $414.71 $13,209 - $21,150	-51 Reduced 0.74%	6,854 $2.37 Million
Q1 2021 Apr 29, 2021	SELL	$242.95 - $284.63 $41,301 - $48,387	-170 Reduced 2.4%	6,905 $1.93 Million
Q4 2020 Jan 28, 2021	SELL	$236.26 - $355.63 $52,449 - $78,949	-222 Reduced 3.04%	7,075 $1.73 Million
Q3 2020 Oct 19, 2020	SELL	$264.77 - $305.71 $29,124 - $33,628	-110 Reduced 1.49%	7,297 $2.07 Million
Q2 2020 Jul 31, 2020	SELL	$258.66 - $342.55 $19,399 - $25,691	-75 Reduced 1.0%	7,407 $1.98 Million
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $26,078 - $33,080	97 Added 1.31%	7,482 $2.37 Million
Q4 2019 Jan 27, 2020	BUY	$220.06 - $304.07 $74,380 - $102,775	338 Added 4.8%	7,385 $2.19 Million
Q3 2019 Oct 29, 2019	SELL	$217.44 - $243.88 $28,484 - $31,948	-131 Reduced 1.83%	7,047 $1.64 Million
Q2 2019 Jul 22, 2019	SELL	$219.29 - $241.72 $309,856 - $341,550	-1,413 Reduced 16.45%	7,178 $1.68 Million
Q1 2019 Apr 30, 2019	BUY	$216.71 - $338.96 $128,292 - $200,664	592 Added 7.4%	8,591 $2.03 Million
Q4 2018 Jan 24, 2019	BUY	$278.5 - $352.75 $27,014 - $34,216	97 Added 1.23%	7,999 $2.67 Million
Q3 2018 Oct 30, 2018	BUY	$293.51 - $383.83 $880 - $1,151	3 Added 0.04%	7,902 $2.79 Million
Q2 2018 Jul 30, 2018	BUY	$257.52 - $306.91 $104,553 - $124,605	406 Added 5.42%	7,899 $2.29 Million
Q1 2018 May 01, 2018	BUY	$260.13 - $367.91 $46,303 - $65,487	178 Added 2.43%	7,493 $2.05 Million
Q4 2017 Feb 02, 2018	SELL	$307.64 - $344.58 $2.21 Million - $2.47 Million	-7,182 Closed	0 $0
Q3 2017 Nov 08, 2017	BUY	$281.15 - $329.69 $2.02 Million - $2.37 Million	7,182	7,182 $2.25 Million

Others Institutions Holding BIIB

# of Institutions

1,047

Shares Held

126M

Call Options Held

1.37M

Put Options Held

1.35M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $33B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dowling & Yahnke LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dowling & Yahnke LLC with notifications on news.

Account

Dowling & Yahnke LLC Biogen Inc. Transaction History